{"id":"NCT04406649","sponsor":"Satsuma Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine","officialTitle":"An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-14","primaryCompletion":"2023-01-16","completion":"2023-01-16","firstPosted":"2020-05-28","resultsPosted":"2023-07-03","lastUpdate":"2023-07-03"},"enrollment":482,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine","Migraine With Aura","Migraine Without Aura"],"interventions":[{"type":"DRUG","name":"Dihydroergotamine","otherNames":["Dihydroergotamine Mesylate"]}],"arms":[{"label":"STS101","type":"EXPERIMENTAL"}],"summary":"Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.","primaryOutcome":{"measure":"Percentage of Participants With Attacks With Sustained Freedom From Headache Pain 2-48 Hours (Modified Intent to Treat Population)","timeFrame":"At Month 12 of Study Medication Dosing","effectByArm":[{"arm":"STS101 5.2 mg","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":["39373843"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":446},"commonTop":["Nasal Discomfort","Dysgeusia","Nausea","Nasal Congestion","COVID-19"]}}